A 51-year-old patient participating in a Phase I study of SRP-9004 for Limb-Girdle muscular dystrophy Type 2E has died due to complications from the gene therapy. This is the third death linked to a Sarepta treatment, similar to two previous fatalities associated with the company’s Duchenne muscular dystrophy gene therapy, Elevidys delandistrogene moxeparvovec, which was caused by acute liver toxicity.
Source: https://www.biocentury.com/article/656520/third-death-from-a-sarepta-gene-therapy